Senti Biosciences Holdings, Inc. business relationships
Companies named in Senti Biosciences Holdings, Inc.’s 10-K filed 2026-03-27, and public companies whose annual reports name Senti Biosciences Holdings, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 12 / 100 Top 2% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in Senti Biosciences Holdings, Inc.’s annual report 4
“For the year ended December 31, 2025, the Company recognized collaboration revenue with Bayer of less than $ 0.1 million in the consolidated statements of operations and comprehensive loss.” SEC filing
“We previously entered into collaborations with Spark Therapeutics (subsidiary of Roche Holding AG) for the design of Smart Sensors for disease- and tissue-specific gene therapy.” SEC filing
“Research Collaboration and License Agreement with Spark Therapeutics, Inc.” SEC filing
“...we have depended on strategic partnerships and collaboration arrangements, such as our collaboration arrangements with BlueRock Therapeutics, Inc., or BlueRock, and Celest Therapeutics, for the application of our gene circuit platform technology to the development and commercialization of potential...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.